

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 661 045 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: **93919648.1**(51) Int. Cl.⁶: **A61K 9/22, A61K 47/34,
A61K 47/36**(22) Date of filing: **10.09.93**(86) International application number:
PCT/JP93/01297(87) International publication number:
WO 94/06414 (31.03.94 94/08)(30) Priority: **18.09.92 JP 274979/92**
08.06.93 JP 165263/93(43) Date of publication of application:
05.07.95 Bulletin 95/27(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL
PT SE**(71) Applicant: **YAMANOUCI PHARMACEUTICAL
CO. LTD.**
No. 3-11 Nihonbashi-Honcho, 2-chome
Chuo-ku
Tokyo 103 (JP)(72) Inventor: **SAKO, Kazuhiro 7-7, Higashikogawa**
4-chome
Yaizu-shi
Shizuoka 425 (JP)Inventor: **NAKASHIMA, Hiroshi 28-2, Mise**
Shizuoka-shi**Shizuoka 422 (JP)**Inventor: **SAWADA, Toyohiro 12-14,**
Kolshigawa-cho 3-chome**Fujieda-shi****Shizuoka 426 (JP)**Inventor: **OKADA, Akira 12-6, Izumi-cho**
Fujieda-shi**Shizuoka 426 (JP)**Inventor: **FUKUI, Muneo 13-14,**
Minamisurugadai 5-chome**Fujieda-shi****Shizuoka 426 (JP)**(74) Representative: **Geering, Keith Edwin**
REDDIE & GROSE
16 Theobalds Road
London WC1X 8PL (GB)(54) **SUSTAINED-RELEASE HYDROGEL PREPARATION.**

(57) A sustained-release hydrogen preparation comprising at least one drug, an additive for making water penetrate into the preparation and a macromolecular substance which forms hydrogel. It can nearly completely gel when it stays in the upper parts of the digestive tract, i.e. the stomach and small intestine, and can release the drug in the lower part thereof, i.e. the colon. The preparation enables the drug to be well dissolved and absorbed even in the colon, thus achieving a stable sustained-release effect.

EP 0 661 045 A1

TECHNICAL FIELD

The present invention relates to a sustained-release preparation capable of releasing a drug for a prolonged period of time. More particularly, the invention relates to a hydrogel-type sustained-release preparation capable of satisfactorily releasing a drug not only in the upper digestive tract but also in the lower digestive tract, particularly in the colon.

BACKGROUND ART

A variety of hydrogel-type preparations have heretofore been proposed for realizing sustained release of drugs. For example, JP-A-62-120315 discloses a preparation obtained by compression-molding a drug, a hydrogel-forming water-soluble polymer and an enteric coating base (the term "JP-A" as used herein means an "unexamined published Japanese patent application"). JP-A-63-215620 discloses a hydrogel-type preparation which comprises a core comprising a drug and a water-soluble polymer and an outer layer comprising a water-soluble polymer as a base. JP-B-40-2053 discloses a sustained-release preparation etc. comprising a mixture of a drug and a high polymer of ethylene oxide and, as an optional component, a hydrophilic substance etc. (the term "JP-B" as used herein means an "examined Japanese patent publication").

However, all of these preparations are designed to release a drug continuously while the administered preparation is still retained in the upper digestive tract, typically in the stomach and small intestine, and are not intended to provide for a release of the drug in the lower digestive tract, typically in the colon, where little water is available. Thus, for any sustained-release preparation designed to release a drug for absorption during its descent down in the digestive tract, the extent of drug release and absorption in the upper digestive tract has a major influence on the bioavailability of the drug. However, it is generally believed that the release of the drug in the colon can hardly be expected because of the paucity of water and the influence of spogenous contents etc. and actually, little research has been undertaken on drug release in colon (Pharm. Tech. Japan 8 (1), (1992), 41).

Furthermore, the biological half-life of a drug *per se* is also an important factor in the design of sustained-release preparations. It has been generally considered difficult to design a preparation providing for dramatic sustained release for a drug having a short half-life period (The Pharmaceuticals Monthly 25 - (11), (1983), 29).

DISCLOSURE OF INVENTION

As a result of extensive studies on the sustained-release of a drug, the inventors of the present invention discovered that the release of a drug in the colon, which is low in water content, can be achieved by providing a preparation adapted to absorb water into its core to undergo substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine, and then move in the form of the gel down to the lower digestive tract. The present invention was achieved based on the above finding.

Thus, the present invention relates to a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive providing for a penetration of water into the core of the preparation, and (3) a hydrogel-forming polymer, which preparation undergoes a substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing a drug in the colon.

The term "substantially complete gelation" of the preparation as used in this specification refers to the state in which not less than about 70%, preferably not less than about 80%, of the preparation is gelled.

Since even the colon can be utilized as a site of absorption, the sustained-release preparation of the present invention prolongs the absorption period of the drug to a remarkable extent and, hence, insures a steady blood level of the drug. Thus, the preparation of the present invention absorbs water during its stay in the upper digestive tract to undergo a substantially complete gelation and then moves down into the lower digestive tract with its surface being constantly eroded, and maintains drug release by further erosion in the lower digestive tract, with the result that a sustained and sufficient absorption of the drug is achieved even in the colon where little water is available.

The sustained-release preparation of the present invention is described in further detail hereinafter.

The drug or drugs which can be used in the preparation according to the present invention are not particularly limited in kind, provided that they are used for sustained-release system.

Thus, representative examples of the drugs include antiinflammatory, antipyretic, anticonvulsant and/or analgesic agents such as indomethacin, diclofenac, diclofenac Na, codeine, ibuprofen, phenylbutazone, oxyphenbutazone, mepirizol, aspirin, ethenzamide, acetaminophen, aminopyrine, phenacetin, scopolamine butylbromide, morphine, etomidolone, pentazocine, fenoprofen calcium, etc.; tuberculostats such as isoniazid, ethambutol hydrochloride, etc.; cardiocirculatory system drugs such as isosorbide dinitrate, nitroglycerin, nifedipine, barnidipine hydrochloride, nicardipine hydrochloride, dipyridamole, amrinone, indenolol hydrochloride, hydralazine hydrochloride, methyl dopa, furosemide, spironolactone, guanethidine nitrate, reserpine, amosulalol hydrochloride, etc.; antipsychotic agents such as chlorpromazine hydrochloride, amitriptyline hydrochloride, nemonapride, haloperidol, moperone hydrochloride, perphenazine, diazepam, lorazepam, chlordiazepoxide, etc.; antihistaminic agents such as chlorpheniramine maleate, diphenhydramine hydrochloride, etc.; vitamins such as thiamine nitrate, tocopherol acetate, cycothiamine, pyridoxal phosphate, cobamamide, ascorbic acid, nicotinamide, etc.; antigout agents such as allopurinol, colchicine, probenecid, etc.; hypnotic sedatives such as amobarbital, bromovalerylurea, midazolam, chloral hydrate, etc.; antineoplastic agents such as fluorouracil, carmofur, aclarubicin hydrochloride, cyclophosphamide, thiotepe, etc.; anticongestants such as phenylpropanolamine, ephedrine, etc.; antidiabetics such as acetohexamide, insulin, tolbutamide, etc.; diuretics such as hydrochlorothiazide, polythiazide, triamterene, etc.; bronchodilators such as aminophylline, formoterol fumarate, theophylline, etc.; antitussives such as codeine phosphate, noscapine, dimemorfan phosphate, dextromethorphan, etc.; antiarrhythmic agents such as quinidine nitrate, digitoxin, propafenone hydrochloride, procainamide, etc.; surface anesthetics such as ethyl aminobenzoate, lidocaine, dibucaine hydrochloride, etc.; antiepileptics such as phenytoin, ethosuximide, primidone, etc.; synthetic adrenocortical steroids such as hydrocortisone, prednisolone, triamcinolone, betamethasone, etc.; digestive system drugs such as famotidine, ranitidine hydrochloride, cimetidine, sucralfate, sulpiride, teprenone, plaunotol, etc.; central nervous system drugs such as indeloxazine, idebenone, tiapride hydrochloride, bifemelane hydrochloride, calcium hopantenate, etc.; hyperlipemia treating agents such as pravastatin sodium etc.; and antibiotics such as ampicillin phthalidyl hydrochloride, cefotetan, josamycin and so on. A typical drug among the above drugs is nicardipine hydrochloride. Drugs having short biological half-lives can also be utilized. The amount of the drug may be any of pharmaceutically effective amount, but is usually below 85 wight %, and preferably below 80 weight % based on the total weight of the preparation.

In order that these drugs may be readily absorbed in the colon which is low in water content, it is preferable to improve their solubilities in advance. Known techniques for improving the solubility of a drug which can be applied to hydrogel preparation can be employed. Among such techniques (solubilizing treatment) can be mentioned the method comprising adding a surfactant (e.g. polyoxyethylene-hydrogenated castor oils, polyoxy-ethylene-sorbitan higher fatty acid esters, polyoxyethylene polyoxypropylene glycols, sucrose fatty acid esters, etc.) and the method comprising preparing a solid dispersion of the drug and a solubilizer such as a polymer (e.g., a water-soluble polymer such as hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), etc. or an enteric polymer such as carboxymethylethylcellulose (CMEC), hydroxypropylmethylcellulose phthalate (HPMCP), methyl methacrylate-methacrylic acid copolymer (Eudragit L and S; the trade name of Rhom & Haas Co.), etc.). When the drug is a basic substance, the method comprising adding an organic acid such as citric acid, tartaric acid or the like can be employed. If necessary, the method involving the formation of a soluble salt or the method comprising forming a clathrate using cyclodextrin or the like can also be employed. These procedures for solubilization can be modified as necessary according to the particular drug.

["Recent Manufacturing Pharmacy Technique and its Application I", Isamu Utsumi et al., *Medicinal Journal*, 157-159 (1983); and "Pharmacy Monograph No. 1, Bioavailability", Tsuneji Nagai et al., Soft-science Co., 78-82 (1988)]

Among these methods, the method comprising preparing a solid dispersion of the drug and a solubilizer is particularly preferred (cf. JP-A-56-49314 and French Patent 2460667).

The additive for allowing water to penetrate into the core of the preparation according to the present invention (this additive for insuring a penetration of water into the preparation core will hereinafter be referred to as "hydrophilic base") is such that the amount of water required to dissolve 1 g of the hydrophilic base is not more than 5 ml and preferably not more than 4 ml at the temperature of $20 \pm 5^\circ \text{C}$. The higher the solubility of the hydrophilic base in water, the more effective is the base in allowing water into the core of the preparation. The hydrophilic base includes, inter alia, highly hydrophilic polymers such as polyethylene glycol (PEG; e.g. PEG400, PEG1500, PEG4000, PEG6000 and PEG20000, produced by Nippon Oils and Fats Co.) and polyvinylpyrrolidone (PVP; e.g. PVP K30, the trade name of BASF), sugar alcohols such as D-sorbitol, xylitol, etc., sugars such as sucrose, anhydrous maltose, D-fructose, dextran (e.g. dextran 40), glucose, etc., surfactants such as polyoxyethylene-hydrogenated castor oil (HCO; e.g.

Cremonophor RH40 produced by BASF, HCO-40 and HCO-60 produced by Nikko Chemicals Co.), polyox-
 ethylene-polyoxypropylene glycol (e.g. Pluronic F68 produced by Asahi Denka Kogyo K.K.), polyox-
 ethylene-sorbitan high molecular fatty acid ester (Tween; e.g. Tween 80 produced by Kanto Kagaku K.K.),
 etc.; salts such as sodium chloride, magnesium chloride, etc.; organic acids such as citric acid, tartaric acid,
 etc.; amino acids such as glycine, β -alanine, lysine hydrochloride, etc.; and amino sugars such as
 5 meglumine.

Preferred ones are PEG6000, PVP, D-sorbitol, etc.

The proportion of such hydrophilic base depends on the characteristics of the drug (solubility,
 therapeutic efficacy, etc.) and content of the drug, solubility of the hydrophilic base itself, characteristics of
 10 the hydrogel-forming polymer used, the patient's condition at the time of administration and other factors.
 However, the proportion may preferably be a sufficient level to achieve a substantially complete gelation
 during the stay of the preparation in the upper digestive tract. The preparation stays in the upper digestive
 tract in a different period depending on the species and the individual but in about 2 hours after
 administration in the case of dogs and in about 4 to 5 hours after administration in the case of human (*Br. J.*
 15 *clin. Pharmac.*, (1988) 26, 435-443). For administration to human, the proportion may preferably be a
 sufficient level to achieve a substantially complete gelation in about 4 to 5 hours after administration. The
 proportion of the hydrophilic base is, therefore, generally about 5-80% by weight and preferably about 5-
 60% by weight based on the total weight of the preparation.

When the content of the hydrophilic base is too small, the necessary gelation into the core of the
 20 preparation does not proceed so that the release of the drug in the colon becomes insufficient. On the other
 hand, when the content of the hydrophilic base is excessive, the gelation proceeds in a shorter time but the
 resulting gel becomes so fragile that the release of the drug is too fast, thus failing to insure a sufficient
 sustained release. Moreover, because the amount of the base is large, the product becomes bulky.

The hydrogel-forming polymer mentioned above should have the physical characteristics, inclusive of
 25 viscosity in the gelled state, which permit the preparation of the present invention to retain its shape more
 or less during its travel down to the lower digestive tract, namely the colon, by withstanding the contractile
 forces of the digestive tract associated with the digestion of food.

The hydrogel-forming polymer which can be used in the preparation of the present invention is
 preferably a polymer showing a high viscosity on gelation. For example, a polymer showing a viscosity of
 30 not less than 1000 cps in 1% aqueous solution (at 25 °C) is particularly preferred.

The properties of the polymer depend on its molecular weight. The hydrogel-forming polymer which
 can be used in the present invention is preferably a substance of comparatively high molecular weight, viz.
 a polymer having an average molecular weight of not less than 2×10^5 and more preferably not less than 4
 $\times 10^5$.

Among such polymers are polyethylene oxide (PEO) having a molecular weight of not less than 2×10^5
 35 [e.g., Polyox WSR-303 (average mol. wt.: 7×10^6 ; viscosity: 7500-10000 cps, 1% in H₂O, 25 °C), Polyox
 WSR Coagulant (average mol. wt.: 5×10^6 ; viscosity: 5500-7500 cps, under the same condition above),
 Polyox WSR-301 (average mol. wt.: 4×10^6 ; viscosity: 1650-5500 cps, under the same condition above),
 Polyox WSR-N-60K (average mol. wt.: 2×10^6 ; viscosity: 2000-4000 cps, 2% in H₂O, 25 °C), all of which
 40 are trade names of Union Carbide Co.]; hydroxypropylmethylcellulose (HPMC) [e.g., Metolose 90SH100000
 (viscosity: 4100-5600 cps, 1% in H₂O, 20 °C), Metolose 90SH50000 (viscosity: 2900-3900 cps, under the
 same condition above), Metolose 90SH30000 (viscosity: 25000-35000 cps, 2% in H₂O, 20 °C), all of which
 are trade names of Shin-Etsu Chemicals Co.]; sodium carboxymethylcellulose (CMC-Na) [e.g., Sanlose F-
 150MC (average mol. wt.: 2×10^5 ; viscosity: 1200-1800 cps, 1% in H₂O, 25 °C), Sanlose F-1000MC
 45 (average mol. wt.: 42×10^4 ; viscosity: 8000-12000 cps, under the same condition above), Sanlose F-300MC
 (average mol. wt.: 3×10^5 ; viscosity: 2500-3000 cps, under the same condition above), all of which are trade
 names of Nippon Seishi Co., Ltd.]; hydroxyethylcellulose (HEC) [e.g., HEC Daicel SE850 (average mol. wt.:
 148×10^4 ; viscosity: 2400-3000 cps, 1% in H₂O, 25 °C), HEC Daicel SE900 (average mol. wt.: 156×10^4 ;
 viscosity: 4000-5000 cps, under the same condition above), all of which are trade names of Daicel Chemical
 50 Industries]; carboxyvinyl polymers [e.g., Carbopol 940 (average mol. wt.: ca. 25×10^5 ; B.F. Goodrich
 Chemical Co.) and so on.

The preferred is a PEO having an average molecular weight of not less than 2×10^5 . Where a
 continuous release of the drug over a long time, for example more than 12 hours, is required, a polymer
 having a higher molecular weight, preferably an average molecular weight of not less than 4×10^5 , or a
 55 higher viscosity, preferably a viscosity of not less than 3000 cps at a concentration of 1% in water at 25 °C,
 is preferable.

The above hydrogel-forming polymer may be used singly, or two or more kind(s) of the above
 hydrogel-forming polymers in mixture may be used. Or, the mixture of two or more kinds of any polymers,

which mixture has characteristics suitable for the present invention, may be suitably used for the present invention.

In order to insure a release of the drug in the human colon, it is necessary that a portion of the preparation having undergone gelation still remain in the colon even as late as at least 6-8 hours, preferably at least 12 hours, after administration.

In order to provide a hydrogel-type preparation having such properties, although it depends on the volume of the preparation, the kind of polymer and the properties and amount of the drug and of the additive for insuring a penetration of water into the preparation core, it is generally preferable that the preparation contains 10-95 weight % (preferably, 15-90 weight %) of the hydrogel-forming polymer based upon the preparation weighing less than 600 mg, and one preparation contains not less than 70 mg per preparation and preferably not less than 100 mg per preparation of the hydrogel-forming polymer. If the amount of this polymer is less than the above-mentioned level, the preparation will not tolerate erosion in the digestive tract for a sufficiently long time and a sufficient sustained release may not be achieved.

Regarding the types and proportions of the hydrophilic base and hydrogel-forming polymer (the latter is hereinafter referred to as hydrogel-forming base), their usefulness has been established by the following experiments.

Experimental Example (Types and Proportions of Hydrophilic Base and Hydrogel-Forming Base)

(1) The time course of gelation velocity of the hydrogel-type sustained-release preparation according to the present invention

Sample

100 parts by weight of hydrogel-forming base Polyox WSR-303 (referred to as POLYOX303 hereinafter) blended with 150 parts by weight of hydrophilic base PEG6000 was mixed in a mortar. The mixed composition was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 8.0 mm in diameter and weighing 200 mg.

Gelation Test

Using The Pharmacopeia of Japan XII (referred to "JP" hereinafter) Disintegration Test Fluid 2, a gelation test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. Sample tablets were taken out at predetermined intervals, the gel layer was removed and the diameter (D obs) of the portion not forming a gel was measured. From this D obs value, the gelation index (G) was calculated (Table 1, Fig. 1 and Equation 1).

The "gelation index" as used herein represents the percentage of the portion of the tablet which has undergone gelation. The method of calculating the gelation index is not particularly limited but the following calculation method may be mentioned as an example.

Thus, the test tablet is moistened for a predetermined time, the volume (or weight) of the portion not forming a gel is then measured and the result is subtracted from the volume (or weight) of the tablet before the beginning of the test.

To be specific, the gel layer of the tablet moistened for a predetermined time is removed, the diameter (or thickness) of the portion not forming a gel is then measured and the gelation index is calculated by means of Equation 1. The gelation index may also be calculated by means of Equation 2 given hereinafter.

As an alternative which takes advantage of the difference in strength between the gel layer and non-gel portion, the diameter (or thickness) under a predetermined pressure is assumed to be the diameter (or thickness) of the portion not forming a gel and the gelation index is calculated from Equation 1.

Table 1

Results of Gelation Test		
Testing Time (h)	D obs (mm)	G (%)
0	8.0±0.0	0
0.5	6.8±0.03	37.9±0.7
1.0	5.8±0.2	61.1±1.8
2.0	4.0±0.05	87.9±0.4
3.0	2.0±0.0	98.4±0.0
4.0	0.0	100
5.0	0.0	100
(n = 3, Mean±S.E.)		

Equation 1

$$\text{Gelation Index (G, \%)} = \left(1 - \frac{(D \text{ obs})^3}{(D \text{ ini})^3} \right) \times 100$$

D obs: The diameter of the portion not gelled after initiation of test
D ini: The diameter of the preparation before initiation of test

Results

The hydrogel tablet containing PEG6000 as a hydrophilic base underwent gelation with its core diameter diminishing progressively at a substantially constant rate. Two hours after the initiation of the test, the hydrogel tablet substantially went through gelation (not less than 80%).

(2) Content of Hydrophilic Base

Samples

One-hundred parts by weight of the hydrogel-forming base POLYOX303 blended with a varying proportion, from 0 to 150 parts by weight, of the hydrophilic base PEG6000 was mixed in a mortar and compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 8.0 mm in diameter and weighing 200 mg.

Gelation Test

Using JP Disintegration Test Fluid No. 2, the gelation test was performed by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. The tablets were taken out at predetermined intervals, the gel layer was stripped off and the diameter (D obs) of the portion not forming a gel was measured. From the D obs value, the gelation index (G) was calculated (Table 2 and Fig. 2).

Table 2

Results of Gelation Test		
Blending Ratio POLYOX303:PEG6000	G (%)	
	2h	4h
100: 0	29.7±2.9	50.5±1.4
100: 5	44.2±5.2	78.0±2.1
100: 10	52.3±2.5	83.9±0.5
100: 15	84.6±0.5	91.2±2.0
100: 25	84.6 ± 0.6	N.T.
100: 50	85.2±0.6	N.T.
100: 100	87.1±0.2	N.T.
100: 150	87.9±0.4	100.0±0.0
N.T.: Not Tested (n = 3, Mean±S.E.)		

Results

It was found that the inclusion of 15 parts by weight (13.0% of tablet weight) of the hydrophilic base PEG6000 resulted in not less than 80% gelation in 2 hours. It was also found that the inclusion of 10 parts by weight (9.1% of tablet weight) of the hydrophilic base PEG6000 resulted in not less than 80% gelation in 4 hours.

(3) Screening of Hydrophilic Bases

Samples

One-hundred parts by weight of the hydrogel-forming base POLYOX303 blended with 100 parts by weight of each test hydrophilic base was mixed in a mortar and compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 8.0 mm in diameter and weighing 200 mg.

Gelation Test

Using JP Disintegration Test Fluid No. 2, the gelation test was performed by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. The tablets were taken out at 2 hours after initiation of the test and the gel layer was stripped off and the diameter (D obs) of the portion not forming a gel was measured. From the D obs value, the gelation index (G) was calculated (Table 3 and Fig. 3).

Table 3

Influence of Solubility of Various Additives on Gelation Index		
Additive	Solubility**	G (%)
No additive		29.7±2.9
Lactose	8 ml	24.4±1.9
D-Mannitol	6 ml	26.8±1.9
Inositol	6 ml	42.0±1.5
Glycine	4 ml	80.9±0.7
PEG20000	4 ml	86.2±0.3
Pluronic F68*	4 ml	95.1±0.4
PVP K30	2 ml	82.2±2.5
Dextran 40	2 ml	85.9±1.0
Meglumine	2 ml	93.4±0.8
Dextrose Anhydrous	2 ml	94.2±1.5
Lysine-HCl	2 ml	95.1±1.3
β -Alanine	2 ml	99.3±0.2
PEG6000	1 ml	87.1±0.2
Citric acid	1 ml	93.2±0.3
Maltose Anhydrous	1 ml	93.7±0.7
Xylitol	1 ml	94.0±1.4
Sucrose	1 ml	94.2±1.1
D-Sorbitol	1 ml	97.0±0.4
D-Fructose	1 ml	100

* Polyoxyethylene[160]polyoxypropylene[30]glycol (n=3, Mean±S.E.)

** Volume of water required for dissolving 1 gram measured in accordance with the method for solubility measurement in JP (25 ± 5 °C)

Results

When D-mannitol and lactose, which require more than 6 ml of water and 8 ml of water for dissolution of 1 g, were respectively added, the systems showed gelation indices comparable to the index of the system using POLYOX303 alone, indicating that these additives are less effective in causing gelation to proceed into the core of the tablet.

It was found that as the hydrophilic base providing for not less than 80% gelation in 2 hours, highly soluble bases (which require not more than 5 ml, preferably not more than 4 ml, of water for dissolution of 1 gram) such as glycine, PVP K30, PEG6000 and D-sorbitol are suitable.

(4) Studies on Hydrogel-Forming Base

Using acetaminophen and nifedipine hydrochloride (Pd) as model drugs, the proportion and molecular weight of a hydrogel-forming base which are necessary for the sustained-release preparation were investigated.

I. Study of Optimum Proportion

The relationship between the proportion of a hydrogel-forming base and the pattern of dissolution was investigated.

1. Acetaminophen

Table 4

Formula (mg)					
Acetaminophen	50	50	50	50	50
PEG6000	50	50	50	50	50
POLYOX303	40	50	100	150	300
Weight (mg)	140	150	200	250	400
Diameter (mm)	6.5	7.0	8.0	8.5	9.5

The components mentioned in Table 4 in the indicated proportions were mixed in a mortar, respectively, and each composition was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets (each containing 50 mg of acetaminophen).

2. Nicardipine Hydrochloride (Pd)

In a mixture of water and methanol (1:9) were dissolved 1 part by weight of Pd, 0.2 part by weight of HCO-60 and 0.4 part by weight of hydroxypropylmethylcellulose (TC-5E, produced by Shin-Etsu Chemical Co.) and the solution was spray-dried using a spray dryer to provide Spray-dried Product 1.

Table 5

Formula (mg)							
Spray-Dried Product	128	128	128	128	128	128	128
PEG6000	32	32	32	32	32	32	32
POLYOX303	64	96	120	160	200	240	320
Weight (mg)	224	256	280	320	360	400	460
Diameter (mm)	8.5	8.5	8.5	9.0	9.0	9.5	10.0

The component materials mentioned in Table 5 in the indicated proportions were respectively mixed in a mortar and each composition was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets (each containing 80 mg of Pd).

Dissolution Test

Using JP Disintegration Test Fluid 1 or 2, the dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) using the acetaminophen and nicardipine hydrochloride (Pd) tablets as models. Sampling was performed at predetermined intervals and the amount of the drug in each sample was determined by the UV method (Figs. 4 and 5).

Results

It was found that the rate of dissolution could be controlled by varying the proportion of the hydrogel-forming base POLYOX303. It was also found that when 50 mg of acetaminophen was used as the principal agent and not less than 100 mg (50% of tablet weight) of POLYOX303 was added, a sustained release of the drug lasting for not less than 12 hours was realized even under vigorous agitation (paddle speed 200 rpm, pH 6.8). Similarly, when 80 mg of Pd was used as the principal agent, the inclusion of not less than 96 mg (37.5% of tablet weight) of POLYOX303 insured a sustained release lasting for not less than 12 hours even under vigorous agitation (paddle speed 200 rpm, pH 1.2).

The optimum proportion of the hydrogel-forming base depends on the types and amounts of the drug and hydrophilic base and the desired dissolution rate, among other factors, but it was found that the larger was the proportion of the hydrogel-forming base, the greater was the sustainment of release. It was also

found that when a sustained release lasting for not less than 12 hours is desired, it is necessary to include not less than about 70 mg, preferably not less than 100 mg, of the hydrogel-forming base per tablet.

II. Study of Relationship between Molecular Weight of Hydrogel-Forming Base and Duration of Release

1. Acetaminophen

Table 6

Formula (Parts by Weight)	
Acetaminophen	50
PEG6000	50
Polyethylene Oxide (PEO)	250

As the polyethylene oxide (PEO), those species having average molecular weights of 9×10^5 , 1×10^6 , 2×10^6 , 4×10^6 , 5×10^6 and 7×10^6 were used. In each case, the component materials were mixed in a mortar and compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 9.0 mm in diameter and weighing 350 mg.

2. Nicardipine Hydrochloride (Pd)

In a mixture of water and methanol (1:9) were dissolved 1 part by weight of Pd, 0.4 part by weight of HCO-40 and 0.8 part by weight of hydroxypropylmethylcellulose (TC-5E, produced by Shin-Etsu Chemical Co.) and the solution was spray-dried using a spray dryer to provide Spray-dried Product 2.

Table 7

Tablet Formula (Parts by Weight)	
Spray-Dried Product 2	178
PEG6000	48
Polyethylene Oxide (PEO)	344

As the polyethylene oxide (PEO), those species having average molecular weights of 9×10^5 , 1×10^6 , 2×10^6 , 4×10^6 , 5×10^6 and 7×10^6 were used. In each case, the component materials were mixed in a mortar and compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 11.0 mm in diameter and weighing 568 mg (containing 80 mg of Pd).

Release Test

The acetaminophen- and nicardipine-containing preparations were tested in the same manner as the dissolution test carried out in I. Study of the Optimal Proportion (Figs. 6 and 7).

Results

The rate of dissolution varied with different average molecular weights of hydrogel-forming base polyethylene oxide (PEO). When 50 mg of acetaminophen was used as the principal agent, the use of PEO with an average molecular weight of not less than 4×10^6 resulted in a sustained release lasting for not less than 12 hours under vigorous agitation (paddle speed 200 rpm, pH 6.8).

Similarly, when 80 mg of Pd was used as the principal agent, the use of PEO with an average molecular weight of not less than 2×10^6 enabled a sustained release lasting for not less than 12 hours.

(5) Verification of In Vivo Gelation

Samples

- 5 The hydrogel-forming base (POLYOX303) and the hydrophilic base (PEG6000, PVP K30, or D-sorbitol) in the ratios indicated below were respectively mixed in a mortar and each mixture was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 8.0 mm in diameter and weighing 200 mg.
- POLYOX303:PEG6000 = 100:10, 25, 50, 100
- 10 POLYOX303:PVP K30 = 100:10, 25, 100
- POLYOX303:D-sorbitol = 100:10, 25, 100

Autopsy Test in Dogs

- 15 Male beagle dogs (Dogs A and B) fasted for about 20 hours were respectively dosed orally with each test preparation, together with 30 ml of water. Two hours later, the animals were anesthetized with pentobarbital Na and, after bleeding, the abdomen was opened. The tablet was recovered from the digestive tract and the D obs value was determined. From this D obs value, the gelation index (G) was calculated (Table 8).

20

25

30

35

40

45

50

55

Table 8: Autopsy Test Data in Dogs

Dog	Sample Administered (POLYOX303 100:)	Position of Recovery	Autopsy Data		In Vitro	
			D obs (mm)	G (%)	D	G (%)
A	PEG6000 10	Colon	6.8	38.6		52.3
	PEG6000 25	Colon	2.8	95.7		84.6
	PEG6000 50	Colon	N.D.	100		85.2
	PEG6000 100	Colon	N.D.	100		87.1
	PVP K30 100	Colon	N.D.	100		82.2
	D-Sorbitol 100	Colon	N.D.	100		97.0
B	PEG6000 10	Stomach	3.2	93.6		52.3
	PEG6000 25	Stomach	2.9	95.2		84.6
	PVP K30 10	Stomach	2.5	96.9		-
	PVP K30 25	Stomach	2.9	95.2		-
	D-Sorbitol 10	Stomach	2.3	97.6		-
	D-Sorbitol 25	Stomach	2.9	95.2		-

N.D.: Not Detected

Results

In Dog A, the tablets had already been transported to the colon by 2 hours after administration and the upper digestive tract residence time was less than 2 hours. In contrast, all the tablets except the one containing 10 parts of PEG6000 had already undergone not less than 80% gelation, generally in agreement

with in vitro data.

In Dog B, the tablets remained in the stomach at 2 hours after administration and all the tablets had undergone more than 80% gelation.

The above results indicated that hydrogel tablets containing a hydrophilic base providing for not less than 80% gelation in vitro (PVP K30, PEG6000 and D-sorbitol) in appropriate amounts are ready to gel due to penetration of water into the tablet core even in vivo.

If necessary, the preparation of the present invention may include appropriate other pharmaceutically acceptable additives such as vehicles (e.g., lactose, mannitol, potato starch, wheat starch, rice starch, corn starch, and crystalline cellulose), binders (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, and gum arabic), swelling agents (e.g., carboxymethylcellulose, carboxymethylcellulose calcium, and cross-linking carboxymethylcellulose sodium), lubricants (e.g., stearic acid, calcium stearate, magnesium stearate, talc, magnesium meta-silicate aluminate, calcium hydrogen phosphate, and anhydrous calcium hydrogen phosphate), fluidizers (e.g., hydrous silica, light anhydrous silicic acid, and dried aluminum hydroxide gel), colorants (e.g., yellow iron sesquioxide and iron sesquioxide), surfactants (e.g., sodium lauryl sulfate, sucrose fatty acid ester), coating agents (e.g., zein, hydroxypropylmethylcellulose, and hydroxypropylcellulose), aromas (e.g., *l*-menthol, peppermint oil, and fennel oil), preservatives (e.g., sodium sorbate, potassium sorbate, methyl *p*-benzoate, and ethyl *p*-benzoate), etc.

The preparation of the present invention is a solid preparation having a certain shape and hydrogel-forming ability, and can be manufactured by the conventional processes utilized for the production of hydrogel preparations. Typical processes are the compression tableting comprising blending the drug, hydrophilic base and hydrogel-forming polymer, if necessary with the addition of other additives, and compression-molding the resulting composition; the capsule compression filling; the extrusion molding comprising fusing a mixture and setting the fused mixture; and the injection molding; etc. Thereafter, any coating treatment such as sugar coating and film coating may be applied or filing into capsules may be carried out.

Solubilization, if performed, of the drug for use in the preparation of the invention can be carried out prior to the above-described manufacturing process. The hydrophilic base according to the present invention may double as said solubilizer in the case that solubilization is carried out. For example, the preparation of the present invention can be manufactured by a process comprising blending the drug, previously solubilized using the hydrophilic base and, if necessary, a different additive, with the hydrogel-forming polymer and, if necessary, other additives, and compression-molding the resulting composition.

If required, the sustained-release preparation of the present invention may have a immediate-release portion. For example, the preparation of the present invention may be provided with such a immediate-release part by way of coating.

Depending on the intended use, the product of the invention can be provided in the form of a dry coated tablet. For example, when a high blood concentration at a definite time after administration is desired, the core tablet is manufactured according to a formulation providing for rapid drug release (with an increased amount of the drug, a reduced amount of the hydrogel-forming base, and/or an increased amount of the hydrophilic base) and, then, the outer layer is formed using a formulation providing for retarded release (with a reduced amount of the drug, an increased amount of the hydrogel-forming base and/or a reduced amount of the hydrophilic base) so that the rate of drug release may be accelerated after a predetermined time.

BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1 shows the results of a gelation test with a PEG6000-containing hydrogel-type sustained-release preparation;
 Fig. 2 shows the results of a gelation test with preparations varying in PEG6000 content;
 Fig. 3 shows the gelation indices of various hydrophilic bases after 2 hours;
 Fig. 4 shows the relationship between the amount of POLYOX303 and the pattern of release (drug: acetaminophen);
 Fig. 5 shows the relationship between the amount of POLYOX303 and the pattern of release (drug: nicardipine hydrochloride);
 Fig. 6 shows the relationship between the molecular weight of PEO and the pattern of release (drug: acetaminophen);
 Fig. 7 shows the relationship between the molecular weight of PEO and the pattern of release (drug: nicardipine hydrochloride);

Fig. 8 shows the results of the dissolution test (paddle method) using the tablets according to Example 1 and Comparative Example 1;

Fig. 9 shows the results of the gelation test using the tablets according to Example 1 and Comparative Example 1;

Fig. 10 shows the time courses of plasma drug concentration in dogs for the tablets according to Example 1 and Comparative Example 1;

Fig. 11 shows a comparison between the dissolution test data and the absorption pattern determined by the deconvolution method for the tablet according to Comparative Example 1;

Fig. 12 shows a comparison between the dissolution test data and the absorption pattern determined by the deconvolution method for the tablet according to Example 1;

Fig. 13 shows the time courses of plasma drug concentration in dogs for the tablets according to Example 2 and Comparative Example 2;

Fig. 14 shows the results of the dissolution test (paddle method) using the tablets according to Example 3 (SR) and Comparative Example 3 (SR);

Fig. 15 shows the time courses of plasma drug concentration in dogs for the tablets according to Example 3 and Comparative Example 3;

Fig. 16 shows the results of the dissolution test (paddle method) using the tablets according to Examples 4 and 5;

Fig. 17 shows the results of the dissolution test (paddle method) using the tablets according to Examples 6, 7 and 10;

Fig. 18 shows the results of the dissolution test (paddle method) using the tablets according to Example 12 and Comparative Example 4;

Fig. 19 shows the time courses of plasma drug concentration in dogs for the tablets according to Example 12 and Comparative Example 4.

BEST MODE FOR WORKING THE INVENTION

The following examples are intended to describe the preparation of the present invention in further detail and should by no means be interpreted as limiting the scope of the invention.

Example 1

AAP	100 (Parts by weight)
PEG6000	400
POLYOX303	300

Acetaminophen (AAP) and PEG6000 were melted at 80 °C, then cooled to solidify, and pulverized. The pulverizate and POLYOX303 were mixed in a mortar and the resulting composition was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 9 mm in diameter and weighing 400 mg (AAP content: 50 mg).

Comparative Example 1

AAP	100 (Parts by weight)
POLYOX303	200

AAP and POLYOX303 were mixed in a mortar and the resulting mixture was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 8.5 mm in diameter and weighing 300 mg (AAP content: 100 mg).

Using the tablets according to Example 1 and Comparative Example 1, the following tests were carried out.

(1) Dissolution Test 1

Using JP Disintegration Test Fluid 2, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method). Sampling was carried out at predetermined intervals and AAP in each sample solution was assayed by the UV method (Table 9 and Fig. 8).

Table 9

Results of In Vitro Dissolution Test (%) (JP Test Fluid 2, Paddle Method, 200 rpm)										
Time (h)	0.0	0.5	1.0	2.0	3.0	4.0	6.0	8.0	10.0	12.0
Comparative Example 1	0.0	9.4	15.7	25.8	34.7	42.8	56.5	68.3	78.4	86.4
Example 1	0.0	8.8	13.2	21.8	32.4	39.1	55.3	69.2	81.9	92.1

(2) Gelation Test

Using JP Disintegration Test Fluid 2, a gelation test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. The tablets were taken out at predetermined intervals and the diameter (D obs) of the portion not forming a gel was measured. From the D obs values thus found, the gelation index (G) was calculated (Table 10 and Fig. 9.).

Table 10

Results of Gelation Test			
Preparation	Testing Time (h)	D obs (mm)	G (%)
Comparative Example 1	0	8.5	-
	2	7.8±0.2	21.5±7.6
	4	7.5±0.1	30.0±2.5
	6	6.7±0.1	50.4±3.0
Example 1	0	9.0	-
	2	5.6±0.03	76.2±0.3
	4	3.1±0.01	96.0±0.1
	6	0 ±0.00	100.0±0
(n=3, Mean±S.E.)			

(3) Dosing Test in Dogs 1

Male beagle dogs (n=4) fasted for about 20 hours were dosed orally with the preparation of Example 1 x 2 tablets (AAP: 100 mg) or the preparation of Comparative Example 1 (AAP: 100 mg), together with 30 ml of water. Blood sampling was carried out at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method (Table 11 and Fig. 10). The absorption rate was calculated by the deconvolution method using the plasma concentration data generated by intravenous administration of 100 mg of AAP in water as the weighing function. The absorption rate at 24 hours after administration of the preparation of Example was taken as 100 (Table 12).

Table 11

Pharmacokinetic Parameters				
Preparation	AUC 0-24 (ng•h/ml)	C max (ng/ml)	T max (h)	MRT (h)
Comparative Example 1	1469.7±537.5	343.7±21.7	1.3±0.3	4.0±1.2
Example 1	2702.8±151.5	349.9±36.1	1.5±0.3	7.0±0.3
(n = 4, Mean±S.E.)				

Table 12: Absorption Rate (%) after
Oral Administration of Tablet to Dogs

Time (h)	0.0	0.5	1.0	2.0	3.0	4.0	6.0	8.0
Comparative Example 1	0.0	8.1	18.7	27.2	33.3	37.8	45.9	50.3
Example 1	0.0	7.5	14.3	31.0	39.1	45.9	60.2	75.5

Time (h)	10.0	12.0	24.0
Comparative Example 1	53.1	55.4	58.8
Example	87.4	95.6	100.0

Results

In the *in vitro* dissolution test, Comparative Example 1 and Example 1 were almost identical in the pattern of dissolution (Fig. 8 and Table 9) but were markedly different from each other in water penetration rate (gelation index) (Fig. 9 and Table 10). When these preparations were administered orally to dogs, the plasma drug concentration after administration of the preparation of Example 1 was definitely well sustained as compared with the preparation of Comparative Example 1 (Fig. 10). Moreover, both the area under the plasma concentration-time curve (AUC) and the mean residence time (MRT) of the preparation of Comparative Example 1 were fairly divergent, presumably because of individual difference in transport rate in the digestive tract (Table 11). In contrast, both the AUC and MRT of the preparation of Example 1 were not much varying; suggesting that this preparation was sparingly influenced by the transport rate in the digestive tract. The absorption time was also extended, with the result that despite the substantial parity of maximum plasma concentration (C max) between the preparation of Example 1 and that of Comparative Example 1, the AUC after administration of the preparation of Example 1 was approximately 1.8 times as

large.

The absorption pattern determined by the deconvolution method was compared with the corresponding dissolution test data. In the case of the preparation of Comparative Example 1, the absorption of the drug during the first 2 hours after administration, when the administered preparation was still in the upper digestive tract, was comparable to the *in vitro* dissolution data. However, the absorption after 2 hours was considerably decreased (Fig. 11 and Table 12). The upper digestive tract residence time of the preparation in fasted dogs is about 2 hours and it is, therefore, clear that the drug was not well released and absorbed in the lower digestive tract. In contrast, after administration of the preparation of Example 1, the pattern of absorption was comparable to the *in vitro* dissolution data. It is, therefore, evident that the drug was released and absorbed in the lower digestive tract as efficiently as in the upper digestive tract (Fig. 12 and Table 12).

(4) Autopsy Test in Dogs

Three male beagle dogs fasted for about 20 hours were used. Two, 4 and 6 hours before autopsy, each test preparation was administered orally together with 30 ml of water. In autopsy, the animals were bled to death under pentobarbital Na anesthesia, the abdomen was opened, and the location of the preparation in the digestive tract was determined (Table 13). The small intestine was divided into 5 segments, which were designated as Small Int. 1, 2, 3, 4 and 5, reckoning from the uppermost segment.

Results

Table 13

Location in Digestive Tract				
	Dog No.	2 Hr	4 Hr	6 Hr
Comparative Example 1	1	Colon	Colon	Colon
	2	Stomach	Colon	Colon
	3	Small Int. 5	Colon	Colon
Example 1	1	Colon	Colon	Colon
	2	Stomach	Colon	Colon
	3	Small Int. 5	Colon	Colon

It is clear that the preparation of Comparative Example 1, which had a low gelation index, and the preparation of Example 1, the gelation index of which had been increased by the addition of hydrophilic base, were substantially identical in the *in vivo* transport rate in digestive tract. At 2 hours after administration, both preparations were still in the stomach in one dog each but were already in Small Int. 5 and colon in the remaining dogs. It was, thus, confirmed that the upper digestive tract residence time of the preparation was approximately 2 hours in fasted dogs in agreement with the findings heretofore reported. However, the high blood concentration after 2 hours following administration of the preparation of Example 1 indicated that the drug was released efficiently from this preparation and absorbed notwithstanding the fact that the preparation was present in the lower digestive tract.

Example 2

Pd	160 (Parts by weight)
HCO-60	80
TC-5E	160
PEG6000	400
POLYOX303	240

Nicardipine hydrochloride (Pd), HCO-60, TC-5E and PEG6000 were dissolved in a solvent mixture (dichloromethane/methanol) and the solution was spray-dried using a spray dryer. This dry preparation was

mixed with POLYOX303 in a mortar and the resulting composition was compression-molded using an oil press at a compression pressure of 1 ton/punch to provide tablets each measuring 9.0 mm in diameter and weighing 346.7 mg (Pd content: 53.3 mg).

5 Comparative Example 2

Pd	130 (Parts by weight)	Sustained-Release (SR) Component
Tween 80	26	
CMEC	130	
POLYOX303	57.2	
Pd	30	Immediate-Release (QR) Component
TC-5E	15	

In a solvent mixture (dichloromethane-methanol) were dissolved nicardipine hydrochloride (Pd), Tween 80 and CMEC and the solution was spray-dried using a spray dryer. The dried mixture was blended with POLYOX303 and the resulting composition was compression-molded using an oil press at a compression pressure of 0.8 ton/punch to provide tablets (SR) each measuring 8.0 mm in diameter and weighing 171.6 mg (Pd content: 65 mg). Separately, Pd and TC-5E were dissolved in a solvent mixture (dichloromethane-methanol) and using a Hi-Coater, this immediate-release component (QR; Pd: 15 mg) was coated on the SR (Pd: 65 mg) component to provide tablets of Comparative Example 2 each weighing 194.1 mg (Pd: 80 mg).

Using the tablets of Example 2 and Comparative Example 2, the following tests were carried out.

25 (1) Dissolution Test

Using JP Disintegration Test Fluid 1, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 200 rpm. Sampling was carried out at predetermined intervals and the Pd in each sample solution was determined by the UV method (Table 14).

Table 14

Results of Dissolution Test									
Time (h)	1.0	2.0	3.0	4.0	5.0	6.0	8.0	10.0	12.0
Comparative Example 2 (SR)	11.9	29.4	46.4	61.9	74.4	82.1	92.1	97.7	100.0
Example 2	14.0	28.7	45.1	60.5	73.1	82.2	94.3	99.8	99.3

40 (2) Gelation Test

Using JP Disintegration Test Fluid 1, a gelation test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. After a testing time of 2 hours, the tablets were taken out and the diameter (D obs) of the portion not forming a gel was measured. From the D obs value thus found, the gelation index (G) was calculated (Table 15).

Table 15

Results of Gelation Test			
Preparation	Testing Time (h)	D obs (mm)	G (%)
Comparative Example 2 (SR)	0	8.0	-
	2	Unchanged	0
Example 2	0	9.0	-
	2	5.4±0.02	76.2±0.3
(n = 3, Mean±S.E.)			

(3) Dosage Test in Dogs

Male beagle dogs (n = 6) fasted for about 20 hours were orally dosed with the preparation of Example 2 x 3 tablets (Pd: 160 mg) or the preparation of Comparative Example 2 x 2 tablets (Pd: 160 mg), together with 30 ml of water. Blood sampling was performed at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method (Table 16 and Fig. 13).

Table 16

Pharmacokinetic Parameters			
Preparation	AUC (ng • h/ml)	C max (ng/ml)	T max (h)
Example 2 (Pd: 160 mg)	375.7±89.3	52.9±15.5	7.3±3.5
Comparative Example 2 (Pd: 160 mg)	125.0±31.8	53.6±12.5	1.3±0.2
(n = 6, Mean±S.E.)			

Results

In the *in vitro* dissolution test, the preparation of Comparative Example 2 (SR) and that of Example 2 were substantially identical in the pattern of dissolution (Table 14) but differed from each other significantly in the rate of water penetration (gelation index) (Table 15). When these preparations were orally administered to dogs, the preparation of Example 2 showed a definitely sustained plasma drug concentration as compared with the preparation of Comparative Example 2. With respect to the preparation of Comparative Example 2, the plasma concentration of the drug decreased significantly after 2 hours when the administered preparation entered into the lower digestive tract, indicating that the drug was hardly released or absorbed in the lower digestive tract. In contrast, in the case that the preparation of Example 2 was administered, the plasma concentration was well maintained even after 2 hours when the preparation was moved into the lower digestive tract, indicating that the drug was effectively released and absorbed in the lower digestive tract. Furthermore, although the preparation of Example 2 showed a C max value comparable to that following administration of the preparation of Comparative Example 2, the former preparation gave an AUC value approximately 3-fold as large due to the prolonged absorption period.

Example 3

Pd	65 (Parts by weight)	Sustained-Release (SR) Component
Tween 80	13	
CMEC	65	
PEG6000	65	
POLYOX303	65	
Pd	15	Immediate-Release (QR) Component

Nicardipine hydrochloride (Pd), Tween 80 and CMEC were dissolved in a solvent mixture (dichloromethanemethanol) and the solution was spray-dried using a spray dryer. The dried mixture was blended with PEG6000 and POLYOX303 and the resulting composition was compression-molded using an oil press at a compression pressure of 1.0 ton/punch to provide tablets (SR) each measuring 8.5 mm in diameter and weighing 273 mg (QR; Pd content: 65 mg). For use as the immediate-release (QR) component, tablets each containing 15 mg of Pd were separately prepared.

Comparative Example 3

Pd	65 (Parts by weight)	Sustained-Release (SR) Component
Tween 80	13	
CMEC	65	
POLYOX303	28.6	
Pd	15	Immediate-Release (QR) Component
TC-5E	7.5	

Nicardipine hydrochloride (Pd), Tween 80 and CMEC were dissolved in a solvent mixture (dichloromethanemethanol) and the solution was spray-dried using a spray dryer. The dried mixture was blended with POLYOX303 and the resulting composition was compression-molded using an oil press at a compression pressure of 0.8 ton/punch to provide tablets (SR) each measuring 8.0 mm in diameter and weighing 171.6 mg (Pd content: 65 mg). Separately, Pd and TC-5E were dissolved in a solvent mixture (dichloromethane-methanol) and using a Hi-Coater, this immediate-release component (QR; Pd content: 15 mg) was coated on the SR component (Pd content: 65 mg) to provide tablets each weighing 194.1 mg (Pd: 80 mg).

(1) Dissolution Test

Using JP Disintegration Test Fluid 2, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 200 rpm. Sampling was carried out at predetermined intervals and Pd in each sample solution was assayed by the UV method.

The results of the above dissolution test using the preparation of Comparative Example 3 (SR) and that of Example 3 (SR) are shown in Fig. 14.

(2) Gelation Test

Using JP Disintegration Test Fluid 1, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. After 2 hours, the tablets were taken out, the gel layer was removed and the weight (W obs) of the portion not forming a gel was determined. From the W obs value, the gelation index (G) was calculated by means of Equation 2 given below (Table 17).

Table 17

Results of Gelation Test (n = 3, Mean±S.E.)			
Preparation	Testing Time (h)	W obs (g)	G (%)
Comparative Example 3 (SR)	0	0.167	-
	2	0.153±0.0	8.2±1.4
Example 3 (SR)	0	0.276	-
	2	0.055±0.4	79.6±0.4

Equation 2

$$G (\%) = \left(1 - \frac{(W \text{ obs})}{(W \text{ ini})} \right) \times 100$$

W obs : The residual weight after removal of the gel layer after initiation of test
W ini : The weight of the tablet before initiation of test

(3) Dosage Test in Dogs

Male beagle dogs (n = 6) fasted for about 20 hours were orally dosed with two tablets each of the preparation of Example 3 SR and QR (Pd: 160 mg) or 2 tablets of the preparation of Comparative Example 3 (Pd: 160 mg), together with 30 ml of water. Blood sampling was performed at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method (Fig. 15 and Table 18).

Table 18

Pharmacokinetic Parameters (n = 6, Mean±S.E.)				
Preparation	AUC 0-24 (ng·h/ml)	C max (ng/ml)	T max (h)	MRT (h)
Comparative Example 3 Example 3	125.0± 31.8	53.6±12.5	1.3±0.2	2.4±0.4
	547.1±180.4	81.6±14.8	3.9±1.1	6.3±1.0

(4) Autopsy Test in Dogs

Three male beagle dogs fasted for about 20 hours were used. Two, 4 and 6 hours before autopsy, each test preparation was administered orally together with 30 ml of water. In autopsy, the animals were bled to death under pentobarbital Na anesthesia, the abdomen was opened, and the location of the tablet in the digestive tract was determined (Table 19). The small intestine was divided into 5 segments, which were designated as Small Int. 1, 2, 3, 4 and 5, reckoning from the uppermost segment.

Table 19

Location in Digestive Tract (Small Intestine was Divided into 5 Segments)				
	Dog No.	2 Hr	4 Hr	6 Hr
Comparative Example 3	4	Colon	Colon	Colon
	5	Colon	Colon	Colon
	6	Small Int. 1	Colon	Colon
Example 3	4	Small Int. 5	Colon	Colon
	5	Colon	Colon	Colon
	6	Small Int. 1	Colon	Colon

Results

In the *in vitro* dissolution test, the preparation of Comparative Example 3 (SR) and that of Example 3 (SR) were substantially identical in the pattern of dissolution (Table 14) but differed considerably from each other in the gelation index (Table 17). Autopsy revealed substantially the same transport rate in the digestive tract for the preparation of Example 3 and that of Comparative Example 3 (Table 19). When these preparations were administered orally to dogs, the time course of plasma drug concentration after administration of the preparation of Example 3 was definitely better sustained as compared with the preparation of Comparative Example 3. With respect to the preparation of Comparative Example 3, the plasma concentration decreased remarkably after 2 hours when the administered preparation was moved into the lower digestive tract, indicating that the drug was hardly released and absorbed in the lower digestive tract. In contrast, with respect to the preparation of Example 3, the plasma drug concentration was well sustained even after 2 hours when the administered preparation was moved into the lower digestive tract, indicating that the drug was effectively released and absorbed even in the lower digestive tract (Fig. 15). Moreover, although the C max after administration of the preparation of Example 3 was not much different from that after administration of the preparation of Comparative Example 3, the former preparation gave an AUC value about 4.4 times as large due to the prolonged absorption period (Table 18).

Example 4

Pd	80 (mg)
PVP K30	32
HCO-60	16
POLYOX303	240
Lubricant	4

Nicardipine hydrochloride (Pd), PVP K30 and HCO-60 were dissolved in methanol. Using a fluidized-bed granulator, this solution was sprayed over POLYOX303 to provide granules. To the granules was added the lubricant and the resulting composition was mixed and then compression-molded to provide tablets each measuring 9.5 mm in diameter and weighing 372 mg (Pd content: 80 mg).

Example 5

5

10

Pd	80 (mg)
TC-5E	32
HCO-60	16
PEG6000	32
POLYOX303	240
Lubricant	8
Fluidizer	4

Nicardipine hydrochloride (Pd), TC-5E and HCO-60 were dissolved in water-methanol (1:9) and the solution was spray-dried. To the dried mixture were added POLYOX303 and 4 mg equivalent of lubricant and the mixture was dry-granulated. To the granules were added 4 mg equivalent of lubricant as well as fluidizer and the resulting composition was mixed and compression-molded to provide tablets each measuring 9.5 mm in diameter and weighing 412 mg (Pd content: 80 mg).

Example 6

20

25

Pd	80 (mg)
TC-5E	32
HCO-60	32
PEG6000	32
POLYOX303	384
Lubricant	11.2
Fluidizer	5.6

30

Nicardipine hydrochloride (Pd), TC-5E, HCO-60 and PEG6000 were dissolved in water-methanol (1:9) and the solution was spray-dried. To this dried preparation were added POLYOX303 and 5.6 mg equivalent of lubricant and the mixture was dry-granulated. To the granules thus prepared were added 5.6 mg equivalent of lubricant as well as fluidizer and the resulting composition was mixed and compression-molded to provide tablets each measuring 11 mm in diameter and weighing 576.8 mg (Pd content: 80 mg).

Example 7

40

45

Pd	80 (mg)
TC-5E	64
Tween 80	32
PEG6000	32
POLYOX303	360
Lubricant	11.4
Fluidizer	5.7

Nicardipine hydrochloride (Pd), TC-5E and Tween 80 were dissolved in water-methanol (1:9) and the solution was spray-dried. To this dried preparation were added PEG6000, POLYOX303 and 5.7 mg equivalent of the lubricant and the mixture was dry-granulated. To the granules thus prepared were added 5.7 mg of lubricant as well as fluidizer and the resulting composition was mixed and compression-molded to provide tablets each measuring 11 mm in diameter and weighing 585.1 mg (Pd content: 80 mg).

Example 8

Pd and TC-5E were dissolved in water-methanol (1:9) and using a Hi-Coater, the immediate-release component (Pd: 20 mg) was coated on the tablets of Example 7 (Pd: 80 mg) to provide tablets each

weighing 625.1 mg (Pd: 100 mg).

Example 9

5 Pd and HPC-SL were dissolved in methanol and using a Hi-Coater, the immediate-release component (Pd: 20 mg) was coated on the tablets of Example 7 (Pd: 80 mg) to provide tablets each weighing 625.1 mg (Pd: 100 mg).

Example 10

10

Pd	80 (mg)
TC-5E	64
HCO-40	32
PEG6000	48
POLYOX303	344
Lubricant	11.4
Fluidizer	5.7

15

20

Pd, TC-5E and HCO-40 were dissolved in water-methanol (1:9) and the solution was spray-dried. To this dried preparation were added PEG6000, POLYOX303 and 5.7 mg equivalent of lubricant and the mixture was dry-granulated. To the granules thus prepared were added 5.7 mg equivalent of lubricant as well as fluidizer and the resulting composition was mixed and compression-molded to provide tablets each measuring 11 mm in diameter and weighing 585.1 mg (Pd content: 80 mg).

25

Example 11

30

Pd	100 (mg)
TC-5E	80
HCO-40	40
PEG6000	48
POLYOX303	300
Lubricant	11.4
Fluidizer	5.7

35

40 Pd, TC-5E and HCO-40 were dissolved in water-methanol (1:9) and the solution was spray-dried. To this dried preparation were added PEG6000, POLYOX303 and 5.7 mg equivalent of lubricant and the mixture was dry-granulated. To the granules were added 5.7 mg equivalent of lubricant as well as fluidizer and the resulting composition was mixed and compression-molded to provide tablets each measuring 11 mm in diameter and weighing 585.1 mg (Pd content: 100 mg).

45 (1) Dissolution Test

Using JP Disintegration Test Fluid 1, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 200 rpm. Sampling was carried out at predetermined intervals and Pd in each sample solution was assayed by the UV method.

50 The results of dissolution tests for preparations of Examples 4 and 5 are shown in Fig. 16.

The results of dissolution tests for preparations of Example 6, Example 7 and Example 10 are shown in Fig. 17.

(2) Dosage Test in Dogs

55

Male beagle dogs (n=6) were orally dosed with 2 tablets of the preparation of Example 5 or 2 tablets of the preparation of Example 6 once a day for 4 consecutive days. Blood sampling was carried out at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method.

Results

Both of the preparations of Examples 5 and 6, in a once-a-day administration, showed high $C_{24 \text{ hr}}$ values (blood concentrations at 24 hours after administration) and high bioavailabilities.

Example 12

DF	37.5 (mg)
PEG6000	37.5
POLYOX303	75.0

Diclofenac Na (DF), PEG6000 and POLYOX303 were mixed in a mortar and using an oil press the composition was compression-molded at a compression pressure of 1 ton/punch to provide tablets measuring 7 mm in diameter and weighing 150 mg (DF: 37.5 mg).

Comparative Example 4

DF	37.5 (mg)
POLYOX303	75.0

DF and POLYOX303 were mixed in a mortar and using an oil press the mixture was compression-molded at a compression pressure of 1 ton/punch to provide tablets each measuring 6.0 mm in diameter and weighing 112.5 mg (DF content: 37.5 mg).

(1) Dissolution Test

Using JP Disintegration Test Fluid 2, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method). Sampling was carried out at predetermined intervals and DF in each sample solution was assayed by the UV method (Fig. 18).

(2) Gelation Test

Using JP Disintegration Test Fluid 2, a gelation test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. The tablets were taken out at 2 hours intervals and the diameter (D obs) of the portion not forming a gel was measured. From the D obs value thus found, the gelation index (G) was calculated (Table 20).

Table 20

Results of Gelation Test (n = 3, Mean \pm S.E.)		
Preparation	Testing Time (h)	G (%)
Example 12	2	88.2 \pm 1.1
Comparative Example 4	2	37.0 \pm 4.6

(3) Dosage Test in Dogs

Male beagle dogs (n = 5) fasted for about 20 hours were orally dosed with the preparation of Example 12 (DF: 37.5 mg) or the preparation of Comparative Example 4 (DF: 37.5 mg), together with 30 ml of water. Blood sampling was carried out at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method (Table 21 and Fig. 19).

Table 21

Oral Dosage Test (in Fasting Condition)			
Preparation	AUC 0-12 (ng•h/ml)	C max (ng/ml)	T max (h)
Comparative Example 4	5052±1357	1188±147	1.7±0.6
Example 12	8537±1941	1381±222	3.0±1.3
(n = 5, Mean±S.E.)			

Results

In the *in vitro* dissolution test, the preparation of Example 12 and that of Comparative Example 4 were substantially identical in the pattern of dissolution (Fig. 18) but differed considerably from each other in the rate of water penetration (gelation index) (Table 20). When these preparations were administered orally to dogs, the preparation of Example 12 showed a definitely prolonged blood concentration as compared with the preparation of Comparative Example 4 (Fig. 19). Furthermore, in comparison with Comparative Example 4, Example 12 gave an AUC value which was about 1.7 times as large (Table 21). Thus, even for diclofenac Na which is an acidic drug, it was confirmed that the application of the present invention resulted in an efficient release and absorption of the drug in the lower digestive tract as well.

Example 13

DF	75 (mg)
PEG6000	75
POLYOX303	150

Diclofenac Na (DF), PEG6000 and POLYOX303 were mixed in a mortar and using an oil press the composition was compression-molded at a compression pressure of 1 ton/punch to provide tablets each measuring 8.5 mm in diameter and weighing 300 mg (DF content: 75 mg).

Example 14

DF	75 (mg)
PEG6000	75
POLYOX303	300

Diclofenac Na (DF), PEG6000 and POLYOX303 were mixed in a mortar and using an oil press the composition was compression-molded at a compression pressure of 1 ton/punch to provide tablets each measuring 9.5 mm in diameter and weighing 450 mg (DF content: 75 mg).

Example 15

Famotidine	40 (mg)
PEG6000	30
POLYOX303	150
Lubricant	2

Famotidine, PEG6000, POLYOX303 and lubricant were mixed and compression-molded to provide tablets each measuring 8.0 mm in diameter and weighing 222 mg (famotidine content: 40 mg).

Example 16

Barnidipine Hydrochloride	15 (mg)
TC-5E	30
HCO-40	5
PEG20000	40
POLYOX303	207
Lubricant	3

Barnidipine hydrochloride, TC-5E and HCO-40 were dissolved in water-methanol (1:9). Separately, PEG20000 and POLYOX303 were mixed. Using a fluidized-bed granulator, the latter mixture was sprayed with the above solution. The granules thus prepared were dried, and after addition of lubricant, the composition was compression-molded to provide tablets each measuring 9.0 mm in diameter and 300 mg (barnidipine HCl content: 15 mg).

Example 17

Amosulalol Hydrochloride	40 (mg)
Pluronic F68	40
POLYOX303	196
Lubricant	4

Amosulalol hydrochloride, Pluronic F68, POLYOX303 and lubricant were mixed, pulverized and dry-granulated. The granules were then compression-molded to provide tablets each measuring 8.5 mm in diameter and weighing 280 mg (amosulalol HCl content: 40 mg).

Example 18

Tamulosin Hydrochloride	0.2 (mg)
D-Sorbitol	17.8
Polyox WSR N-60K	180
Lubricant	2

Tamulosin hydrochloride, D-sorbitol and PEO (Polyox WSR N-60K) were wet-granulated with ethanol and dried. To this dried granules was added lubricant and the resulting composition was mixed and then compression-molded to provide tablets each measuring 8 mm in diameter and weighing 200 mg (tamulosin HCl content: 0.2 mg).

Example 19

Indeloxazine Hydrochloride	60 (mg)
Sucrose	37
HPMC (90SH30000)	180
Lubricant	3

Indeloxazine hydrochloride, sucrose, HPMC and lubricant were mixed and dry-granulated. The granules were then compression-molded to provide tablets each measuring 9 mm in diameter and 280 mg (indeloxazine HCl content: 60 mg).

Example 20

Formoterol Fumarate	0.16 (mg)
Anhydrous Maltose	47.84
Carbopol 940	100
Lubricant	2

Formoterol fumarate, anhydrous maltose, Carbopol 940 and lubricant were mixed and the resulting composition was compression-molded to provide tablets each measuring 7 mm in diameter and weighing 150 mg (formoterol fumarate content: 0.2 mg).

Example 21

AAP	100 (mg)
PEG6000	200
PEO (Polyox WSR N-60K)	300

Acetaminophen (AAP), PEG6000 and PEO (Polyox WSR N-60K, mean molecular weight: 200 million) were mixed in a mortar and using an oil press the mixture was compression-molded at a pressure of 1 ton/punch to provide tablets each measuring 11 mm in diameter and weighing 600 mg (AAP content: 100 mg).

Comparative Example 5

AAP	100 (mg)
PEO (Polyox WSR N-60K)	300

AAP and PEO (POLYOX WSR N-60K) were mixed in a mortar and using an oil press the mixture was compression-molded at a pressure of 1 ton/punch to provide tables each measuring 9 mm in diameter and weighing 400 mg (AAP content: 100 mg).

(1) Dissolution Test

Using JP Disintegration Test Fluid 2, a dissolution test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 200 rpm. Sampling was carried out at predetermined intervals and AAP in each sample solution was assayed by the UV method.

(2) Gelation Test

Using JP Disintegration Test Fluid 2, a gelation test was carried out by JP Dissolution Test Method 2 (paddle method) at a paddle speed of 25 rpm. After 2 hours, the tablets were taken out and the diameter (D obs) of the portion not forming a gel was measured. From the D obs value thus found, the gelation index (G) was calculated.

(3) Dosage Test in Dogs

Male beagle dogs (n = 6) fasted for about 20 hours were orally dosed with the preparation of Comparative Example 5 (AAP: 100 mg) or the preparation of Example 20 (AAP: 100 mg), together with 30 ml of water. Blood sampling was carried out at predetermined intervals and the plasma concentration of the drug was determined by the HPLC/UV method.

Results

In the *in vitro* dissolution test, the preparation of Comparative Example 5 and that of Example 20 were substantially identical in the pattern of dissolution but the preparation of Example 20, which contained a hydrophilic base, showed a gelation index greater than that of the preparation of Comparative Example 5. When these preparations were respectively administered orally to dogs, the plasma concentration of the drug was definitely better sustained in the case of Example 21 as compared with Comparative Example 5. The maximum plasma concentration (C max) of the drug after administration of the preparation of Example 21 was substantially equal to that after administration of the preparation of Comparative Example 5 but the former preparation was superior in AUC and MRT. Moreover, after administration of the preparation of Example 21, the blood concentration of the drug was sustained at a high level up to 12 hours.

Industrial Applicability

The preparation of the present invention absorbs water to undergo substantially complete gelation during its stay in the upper digestive tract and moves down into the lower digestive tract undergoing constant erosion and continues to release the drug on further erosion. Therefore, this preparation provides for a favorable sustained release of the drug even in the colon which is low in water content to insure drug release lasting for about 6 to 18 hours (about 12 to 24 hours if the release in the upper digestive tract is taken into account) and, hence, insures a steady drug concentration in the blood.

Since the conventional sustained-release preparations release drugs only in the upper digestive tract, the duration of release is about 6 hours at most and subsequent maintenance of blood concentration is relied on the biological half-life inherent to the drug. In contrast, with respect to the preparation of the present invention, the duration of drug release *per se* is increased. Accordingly, even when the drug is that having a short biological half-life and the sustained release thereof has heretofore been considered difficult, a sufficient blood concentration can be maintained over a time period of more than 12 hours.

Thus, the preparation of the present invention is capable of sustaining the efficacy of the drug and the number of administration can be reduced. Further, the side effect of the drug can be reduced by suppressing rapid increase of blood concentration of the drug and the constant blood concentration of the drug can be maintained.

As demonstrated in the examples described above, the present invention is capable of prolonging the absorption of various types of drugs such as acetaminophen, which is a neutral drug, nifedipine hydrochloride, which is a basic drug, and diclofenac Na, which is an acidic drug. Therefore, the present invention provides a pharmaceutical technology having a great versatility without depending on physical properties of drugs.

Claims

1. A hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract including stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon.
2. The hydrogel-type sustained-release preparation according to claim 1, wherein said additive which insures a penetration of water into the core of the preparation is at least one additive having a solubility that the volume of water required for dissolving 1 gram of said additive is not more than 5 ml.
3. The hydrogel-type sustained-release preparation according to claim 2, wherein said additive which insures a penetration of water into the core of the preparation is at least one additive having a solubility that the volume of water required for dissolving 1 gram of said additive is not more than 4 ml.
4. The hydrogel-type sustained-release preparation according to claim 1, wherein said hydrogel-forming polymer is either a polymer having an average molecular weight of not less than 2,000,000 or a polymer having a viscosity of not less than 1000 cps as measured at 1% concentration in water at 25 °C, or a mixture of two or more of these polymers.

5. The hydrogel-type sustained-release preparation according to claim 1 or 4, wherein said hydrogel-forming polymer includes at least one polyethylene oxide.
- 5 6. The hydrogel-type sustained-release preparation according to any one of claims 1 to 5, which comprises (1) at least one drug in an amount of not more than 85% by weight based on the total preparation, (2) an additive which insures a penetration of water into the core of the preparation in an amount of from 5 to 80% by weight based on the total preparation, and (3) a hydrogel-forming polymer in an amount of from 10 to 95% by weight based on the total preparation.
- 10 7. The hydrogel-type sustained-release preparation according to any one of claims 1 to 6, which comprises (1) at least one drug in an amount of not more than 80% by weight based on the total preparation, (2) an additive which insures a penetration of water into the core of the preparation in an amount of from 5 to 60% by weight based on the total preparation, and (3) a hydrogel-forming polymer in an amount of from 15 to 90% by weight based on the total preparation.
- 15 8. The hydrogel-type sustained-release preparation according to any one of claims 1 to 7, wherein said drug is nicardipine hydrochloride.

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18





Fig. 19



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP93/01297

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁵ A61K9/22, A61K47/34, 47/36

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁵ A61K9/20-9/42, A61K47/30-47/38, A61K31/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP, A, 3-2119 (The Procter & Gamble Co.), January 8, 1991 (08. 01. 91), (Family: none)	1
A	JP, A, 3-34927 (Teikoku Seiyaku K.K.), February 14, 1991 (14. 02. 91), (Family: none)	1
A	JP, A, 4-501411 (Beringer Ingerheim Italia S.p.A.), March 12, 1992 (12. 03. 92), & EP, A, 366621 & US, A, 5171580	1
A	JP, A, 4-217924 (Teikoku Seiyaku K.K.), August 7, 1992 (07. 08. 92), (Family: none)	1

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

November 30, 1993 (30. 11. 93)

Date of mailing of the international search report

December 21, 1993 (21. 12. 93)

Name and mailing address of the ISA/

Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.